Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docx
Introduction<p>Although the transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab improves outcomes in unresectable HCC (uHCC), predictive tools are lacking. This study developed and validated a prognostic model for triple therapy efficacy.</p>Methods&l...
Saved in:
| 主要作者: | |
|---|---|
| 其他作者: | , , , , , , , , , |
| 出版: |
2025
|
| 主題: | |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| _version_ | 1849927636623556608 |
|---|---|
| author | Liying Ren (11143129) |
| author2 | Dongbo Chen (10430738) Xue Zhang (166886) Shaoping She (22678979) Ran Fei (93650) Xu Cong (159269) Shaowei Mu (22678982) Yuchen Zhou (1601536) Jie Gao (10266) Weijia Liao (492662) Hongsong Chen (159274) |
| author2_role | author author author author author author author author author author |
| author_facet | Liying Ren (11143129) Dongbo Chen (10430738) Xue Zhang (166886) Shaoping She (22678979) Ran Fei (93650) Xu Cong (159269) Shaowei Mu (22678982) Yuchen Zhou (1601536) Jie Gao (10266) Weijia Liao (492662) Hongsong Chen (159274) |
| author_role | author |
| dc.creator.none.fl_str_mv | Liying Ren (11143129) Dongbo Chen (10430738) Xue Zhang (166886) Shaoping She (22678979) Ran Fei (93650) Xu Cong (159269) Shaowei Mu (22678982) Yuchen Zhou (1601536) Jie Gao (10266) Weijia Liao (492662) Hongsong Chen (159274) |
| dc.date.none.fl_str_mv | 2025-11-25T06:15:26Z |
| dc.identifier.none.fl_str_mv | 10.3389/fimmu.2025.1692632.s001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Data_Sheet_1_Development_and_validation_of_the_FAAP_model_for_prognostic_stratification_in_HCC_patients_treated_with_TACE_sintilimab_plus_bevacizumab_a_multicenter_study_docx/30703664 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Genetic Immunology hepatocellular carcinoma immunotherapy transcatheter arterial chemoembolization prognostic model FAAP score |
| dc.title.none.fl_str_mv | Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docx |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | Introduction<p>Although the transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab improves outcomes in unresectable HCC (uHCC), predictive tools are lacking. This study developed and validated a prognostic model for triple therapy efficacy.</p>Methods<p>A multicenter study enrolled uHCC patients receiving TACE-sintilimab-bevacizumab. Overall survival (OS) was the primary endpoint; a Cox model was developed and validated.</p>Results<p>This study enrolled 147 patients (training cohort: n = 92; validation cohort: n = 55). The optimal cutoff value for the fibrin degradation product-to-cholinesterase ratio*1000 (FCR) was determined as 0.8. Univariate and multivariate Cox regression analyses identified FCR, AST, AFP, and PVTT as independent OS predictors. These variables were integrated to establish the FAAP scoring system, which demonstrated robust discriminative performance with AUC of 0.804 (95% CI: 0.703-0.893) and 0.799 (95% CI: 0.67-0.911) in the training and validation cohorts, respectively. Patients were stratified into three risk groups based on FAAP scores: low (FAAP < 0.7), intermediate (0.7 ≤ FAAP < 2.2), and high (FAAP ≥ 2.2). Kaplan-Meier analyses revealed significant prognostic stratification for both OS and progression-free survival (PFS) across groups. Subgroup analyses confirmed the prognostic relevance of FAAP scores in key clinical subsets, including age, gender, extrahepatic metastasis status, viral hepatitis etiology, PVTT presence, and Child-Pugh stage.</p>Conclusions<p>The FAAP scoring system effectively predicted survival outcomes in HCC patients receiving TACE-sintilimab-bevacizumab therapy, which suggests its clinical utility for prognostic prediction. Further large prospective studies are required for external validation.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_736892b97eef22adb69aab0edd85ec53 |
| identifier_str_mv | 10.3389/fimmu.2025.1692632.s001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30703664 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docxLiying Ren (11143129)Dongbo Chen (10430738)Xue Zhang (166886)Shaoping She (22678979)Ran Fei (93650)Xu Cong (159269)Shaowei Mu (22678982)Yuchen Zhou (1601536)Jie Gao (10266)Weijia Liao (492662)Hongsong Chen (159274)Genetic Immunologyhepatocellular carcinomaimmunotherapytranscatheter arterial chemoembolizationprognostic modelFAAP scoreIntroduction<p>Although the transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab improves outcomes in unresectable HCC (uHCC), predictive tools are lacking. This study developed and validated a prognostic model for triple therapy efficacy.</p>Methods<p>A multicenter study enrolled uHCC patients receiving TACE-sintilimab-bevacizumab. Overall survival (OS) was the primary endpoint; a Cox model was developed and validated.</p>Results<p>This study enrolled 147 patients (training cohort: n = 92; validation cohort: n = 55). The optimal cutoff value for the fibrin degradation product-to-cholinesterase ratio*1000 (FCR) was determined as 0.8. Univariate and multivariate Cox regression analyses identified FCR, AST, AFP, and PVTT as independent OS predictors. These variables were integrated to establish the FAAP scoring system, which demonstrated robust discriminative performance with AUC of 0.804 (95% CI: 0.703-0.893) and 0.799 (95% CI: 0.67-0.911) in the training and validation cohorts, respectively. Patients were stratified into three risk groups based on FAAP scores: low (FAAP < 0.7), intermediate (0.7 ≤ FAAP < 2.2), and high (FAAP ≥ 2.2). Kaplan-Meier analyses revealed significant prognostic stratification for both OS and progression-free survival (PFS) across groups. Subgroup analyses confirmed the prognostic relevance of FAAP scores in key clinical subsets, including age, gender, extrahepatic metastasis status, viral hepatitis etiology, PVTT presence, and Child-Pugh stage.</p>Conclusions<p>The FAAP scoring system effectively predicted survival outcomes in HCC patients receiving TACE-sintilimab-bevacizumab therapy, which suggests its clinical utility for prognostic prediction. Further large prospective studies are required for external validation.</p>2025-11-25T06:15:26ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fimmu.2025.1692632.s001https://figshare.com/articles/dataset/Data_Sheet_1_Development_and_validation_of_the_FAAP_model_for_prognostic_stratification_in_HCC_patients_treated_with_TACE_sintilimab_plus_bevacizumab_a_multicenter_study_docx/30703664CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/307036642025-11-25T06:15:26Z |
| spellingShingle | Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docx Liying Ren (11143129) Genetic Immunology hepatocellular carcinoma immunotherapy transcatheter arterial chemoembolization prognostic model FAAP score |
| status_str | publishedVersion |
| title | Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docx |
| title_full | Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docx |
| title_fullStr | Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docx |
| title_full_unstemmed | Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docx |
| title_short | Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docx |
| title_sort | Data Sheet 1_Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.docx |
| topic | Genetic Immunology hepatocellular carcinoma immunotherapy transcatheter arterial chemoembolization prognostic model FAAP score |